In Brief: Device investigator disqualification
This article was originally published in The Gray Sheet
Executive Summary
Device investigator disqualification: FDA publishes final rule in March 14 Federal Register spelling out criteria for disqualification of researchers from investigational device exemption studies. The reg amends a quirk in the investigational device exemption reg which only permitted FDA's device center to disqualify clinical investigators engaged in intraocular lens trials. The final rule, which contains sections outlining "Grounds for Disqualification," "Notification of Disqualification," "Actions Upon Disqualification," "Reinstatement of a Disqualified Investigator" and "Scope," is similar to investigator disqualification regs for drugs, biologics, and animal drugs, and finalizes a 1993 proposed rule ("The Gray Sheet" June 21, 1993, p. 3)...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.